Prime Medicine, Inc. (PRME) Stock Forecast Nov. 5, 2026
Analysis updated on Nov. 5, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Prime Medicine, Inc. (PRME) stock forecast summary
Our AI scores Prime Medicine, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Prime Medicine, Inc. is a small-cap company with a market capitalization of $799M. It ranks number 50 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For PRME, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 38.0%, measured on 345 forecast dates between 2022-11-17 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 387 forecast dates between 2022-11-17 and 2026-10-06. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PRME included.
PRME price chart and AI forecast
How PRME ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Prime Medicine, Inc. (PRME) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | PRME | Rank |
|---|---|---|
| Market Cap | $799M | 50/60 |
| P/B Ratio | 20.07x | 7/48 |
| EPS | $-1.18 | – |
| Book Value/Share | $0.25 | – |
| FCF/Share | $-0.98 | – |
Profitability & Margins
| Metric | PRME | Rank |
|---|---|---|
| ROE | -472.0% | 43/44 |
| ROA | -75.5% | 43/47 |
| ROIC | -90.4% | 50/52 |
| Operating Margin | -4893.4% | 40/41 |
| Net Margin | -4678.6% | 35/36 |
| EBT Margin | -4893.4% | 42/43 |
| Tax Rate | 0.0% | – |
Financial Health
| Metric | PRME | Rank |
|---|---|---|
| Current Ratio | 3.05x | 45/59 |
| D/E Ratio | 5.26x | 2/52 |
| Financial Leverage | 6.26x | 2/51 |
| Working Capital | $65M | 55/58 |
Cash Flow
| Metric | PRME | Rank |
|---|---|---|
| Operating Cash Flow | -$156M | 31/56 |
| Free Cash Flow | -$157M | 29/49 |
| Capital Spending | -$800K | 9/49 |
Income Statement
| Metric | PRME | Rank |
|---|---|---|
| Operating Income | -$197M | 28/53 |
| Net Income | -$188M | 26/47 |
| R&D Expense | $146M | 38/55 |
Dividend & Shareholder Information
| Metric | PRME | Rank |
|---|---|---|
| Shares Outstanding | 161M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $97M | 38.9% of assets |
| Cash & Short-term Investments | $47M | 19.1% of assets |
| Total Liabilities | $209M | 84.0% of assets |
| Short-term Debt | $26M | 10.4% of assets |
PRME quarterly financials and insider trading
Prime Medicine, Inc. (PRME) industry peers
Companies classified under the same SEC industry code as Prime Medicine, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PRME Prime Medicine, Inc. | $799M | |
| AMGN Amgen Inc | $248.84B | |
| GILD Gilead Sciences, Inc. | $207.84B | |
| MRNA Moderna, Inc. | $96.40B | |
| ARGX Argenx Se | $55.37B | |
| RVMD Revolution Medicines, Inc. | $42.80B | |
| BIIB Biogen Inc. | $36.06B | |
| BNTX Biontech Se | $21.71B | |
| EXEL Exelixis, Inc. | $16.77B | |
| NBIX Neurocrine Biosciences Inc | $16.24B | |
| HALO Halozyme Therapeutics, Inc. | $13.96B | |
| TECH Bio-Techne Corp | $11.41B | |
| QGEN Qiagen N.V. | $11.03B | |
| KYMR Kymera Therapeutics, Inc. | $10.94B | |
| RGEN Repligen Corp | $10.77B | |
| PCVX Vaxcyte, Inc. | $9.77B | |
| KRYS Krystal Biotech, Inc. | $8.90B | |
| IBRX Immunitybio, Inc. | $8.49B | |
| TWST Twist Bioscience Corp | $7.56B | |
| IMVT Immunovant, Inc. | $5.86B | |
| CGON Cg Oncology, Inc. | $5.74B | |
| KOD Kodiak Sciences Inc. | $5.72B | |
| SRRK Scholar Rock Holding Corp | $5.54B | |
| CRSP Crispr Therapeutics Ag | $4.70B | |
| ADPT Adaptive Biotechnologies Corp | $4.28B | |
| RLAY Relay Therapeutics, Inc. | $3.95B | |
| IOVA Iovance Biotherapeutics, Inc. | $3.51B | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.33B | |
| DNLI Denali Therapeutics Inc. | $3.15B | |
| ADMA Adma Biologics, Inc. | $2.96B | |
| BEAM Beam Therapeutics Inc. | $2.67B | |
| COAG Hemab Therapeutics Holdings, Inc. | $2.13B | |
| VCEL Vericel Corp | $2.10B | |
| LIFE Atyr Pharma Inc | $2.08B | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.08B | |
| REPL Replimune Group, Inc. | $1.96B | |
| BCRX Biocryst Pharmaceuticals Inc | $1.95B | |
| VIR Vir Biotechnology, Inc. | $1.86B | |
| MAZE Maze Therapeutics, Inc. | $1.81B | |
| MESO Mesoblast Ltd | $1.81B | |
| ALVO Alvotech | $1.62B | |
| NVAX Novavax Inc | $1.61B | |
| IMCR Immunocore Holdings Plc | $1.46B | |
| TSHA Taysha Gene Therapies, Inc. | $1.33B | |
| VOR Vor Biopharma Inc. | $1.15B | |
| CGEM Cullinan Therapeutics, Inc. | $1.01B | |
| ODTX Odyssey Therapeutics, Inc. | $907M | |
| GLUE Monte Rosa Therapeutics, Inc. | $874M | |
| IMTX Immatics N.V. | $829M | |
| MGTX Meiragtx Holdings Plc | $817M | |
| SANA Sana Biotechnology, Inc. | $700M | |
| SLDB Solid Biosciences Inc. | $699M | |
| SLBT Sl Science Holding Ltd | $679M | |
| DNA Ginkgo Bioworks Holdings, Inc. | $671M | |
| AURA Aura Biosciences, Inc. | $657M | |
| FDMT 4d Molecular Therapeutics, Inc. | $621M | |
| DBVT Dbv Technologies S.A. | $616M | |
| CADL Candel Therapeutics, Inc. | $615M | |
| VALN Valneva Se | $551M | |
| ENTX Entera Bio Ltd. | $518M |
Where PRME sits on the market map
Prime Medicine, Inc. (PRME) stock news
Loading...
Prime Medicine, Inc. (PRME) stock forecast FAQ
What is the Prime Medicine, Inc. (PRME) stock forecast?
Our AI scores Prime Medicine, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Prime Medicine, Inc. stock predictions?
For PRME, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 38.0%, measured on 345 forecast dates between 2022-11-17 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 16.0%, measured on 387 forecast dates between 2022-11-17 and 2026-10-06. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Prime Medicine, Inc. forecasts updated?
Prime Medicine, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 5, 2026.
Which companies are Prime Medicine, Inc.'s industry peers?
60 issuers in our coverage, PRME included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.